Rating #102
Tom Steyer
Farallon Capital Management
Portfolio value
Stocks
Performance
1 Year
+12.25%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Tom Steyer’s Portfolio: Q1 2026
Top10 stocks: 48.43% of the portfolio
Tom Steyer’s Trades: Q1 2026
Adds
New Buys
Sold Outs
Cuts
1.74ppt
1.30ppt
1.52ppt
0.79ppt
0.80ppt
0.62ppt
0.05ppt
0.42ppt
0.42ppt
0.51ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  AVGO | Add +99.41% | $329.05 | $291.90M | 1.74ppt | |
2  KKR | Add +131.54% | $105.41 | $279.77M | 1.30ppt | |
3  ROIV | Add +26048.65% | $25.69 | $247.60M | 1.52ppt | |
4  MA | Add +151.97% | $526.66 | $138.20M | 0.79ppt | |
5  TMO | Add +38.67% | $542.70 | $133.40M | 0.80ppt | |
6  SNPS | Add +21.43% | $452.07 | $96.79M | 0.62ppt | |
7  GRAL | Add +38.89% | $77.46 | $70.57M | 0.05ppt | |
8  PCVX | Add +25120.00% | $54.29 | $68.19M | 0.42ppt | |
9  UNH | Add +13.93% | $297.81 | $66.35M | 0.42ppt | |
10  GOOG | Add +26.58% | $314.16 | $65.72M | 0.51ppt |
Tom Steyer’s Holdings: Q1 2026
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
- | $650.34 | New Buy +100.00% | 2.30M | $1.50B | 8.53% 8.53ppt | - | 1 Quarter | Q1 2026 | ||
2  RVMD | Biological products | $35.28 | Cut -6.71% | 13.60M | $1.32B | 7.54% 2.28ppt | 7.16% | 21 Quarters | Q1 2026 | |
3  AMZN | Retail-Catalog & Mail-Order | $221.93 | Cut -6.26% | 4.22M | $878.56M | 5.01% 0.30ppt | 0.04% | 4 Quarters | Q1 2026 | |
4  MSFT | Prepackaged Software | $342.31 | Add +5.90% | 2.34M | $867.97M | 4.95% 0.10ppt | 0.03% | 51 Quarters | Q1 2026 | |
5  AON | Insurance Agents & Brokers | $331.96 | Cut -5.73% | 2.51M | $811.03M | 4.62% 0.36ppt | 1.17% | 24 Quarters | Q1 2026 | |
6  BBIO | Pharmaceutical Pres | $38.71 | Add +4.08% | 9.37M | $695.48M | 3.96% 0.85ppt | 4.75% | 7 Quarters | Q1 2026 | |
7  PTGX | Pharmaceutical Pres | $22.56 | Add +3.34% | 6.35M | $669.17M | 3.81% 1.38ppt | 9.99% | 34 Quarters | Q1 2026 | |
8  NTRA | Medical Laboratories | $74.68 | Cut -18.06% | 3.21M | $641.44M | 3.66% -0.41ppt | 2.35% | 20 Quarters | Q1 2026 | |
9  EXEL | Biological products | $23.27 | Cut -16.54% | 13.11M | $562.33M | 3.21% 0.09ppt | 4.83% | 31 Quarters | Q1 2026 | |
10 AVGO | Semiconductors | $327.86 | Add +99.41% | 1.78M | $550.77M | 3.14% 1.74ppt | 0.04% | 2 Quarters | Q1 2026 | |
11 UNH | Medical Service Plans | $433.66 | Add +13.93% | 1.82M | $492.94M | 2.81% 0.42ppt | 0.20% | 13 Quarters | Q1 2026 | |
12 SNPS | Prepackaged Software | $456.80 | Add +21.43% | 1.21M | $481.05M | 2.74% 0.62ppt | 0.76% | 2 Quarters | Q1 2026 | |
13  BSX | Surgical Instruments | $73.75 | Add +0.42% | 7.47M | $468.79M | 2.67% -0.54ppt | 0.50% | 23 Quarters | Q1 2026 | |
14 TMO | Other Measuring Devices | $465.67 | Add +38.67% | 881.49K | $433.28M | 2.47% 0.80ppt | 0.23% | 26 Quarters | Q1 2026 | |
15 KKR | Investment Advice | $107.61 | Add +131.54% | 4.67M | $432.14M | 2.46% 1.30ppt | 0.52% | 2 Quarters | Q1 2026 | |
16  LNTH | Diagnostic Substances | $78.08 | Add +2.87% | 5.58M | $423.51M | 2.41% 0.78ppt | 8.27% | 13 Quarters | Q1 2026 | |
17  WAB | Railroad Equipment | $147.51 | Cut -35.00% | 1.61M | $402.21M | 2.29% -0.10ppt | 0.95% | 37 Quarters | Q1 2026 | |
18  SCHW | Security Brokers & Dealers | $78.74 | Add +18.45% | 3.96M | $371.75M | 2.12% 0.61ppt | 0.22% | 6 Quarters | Q1 2026 | |
19  LQDA | Pharmaceutical Pres | $18.25 | 0.00% | 8.66M | $326.68M | 1.86% 0.51ppt | 10.06% | 9 Quarters | Q4 2025 | |
20  CRNX | Pharmaceutical Pres | $45.18 | Add +20.27% | 8.34M | $302.84M | 1.73% 0.26ppt | 8.86% | 11 Quarters | Q1 2026 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.